Form 4: Q32 Bio Inc. Director Mary Thistle Acquires Stock Options
SEC Filing (Form 4)
Director Mary Thistle acquired stock options for 12,767 shares of Q32 Bio Inc. on March 25, 2024.
Summary
- On March 25, 2024, Mary Thistle, a director of Q32 Bio Inc., acquired stock options for 12,767 shares.
- The exercise price of these options is $16.82 per share.
- One-third of the options will vest on March 25, 2025, with the remainder vesting in equal monthly installments over the following 24 months, contingent upon continued service.
- Following the transaction, Mary Thistle directly owns 12,767 derivative securities.
Sentiment
Score: 7
Explanation: The document indicates a standard transaction of stock options being granted to a director, suggesting a neutral to slightly positive sentiment as it aligns the director's interests with the company's success.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Future Outlook
The vesting schedule of the options is tied to continued service, incentivizing the director to remain with the company.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of the stock option acquisition. |
| 03/25/2025 | Date when one-third of the stock options begin to vest. |
| 03/24/2034 | Expiration date of the stock options. |
| 03/27/2024 | Date of the Power of Attorney execution. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.